Pancreatic Cancer Research

ResearcherAichi Medical UniversityActive in the last 2 years

Suguru Yamada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9912-9119; OpenAlex author ID A5022391772. Sources: OpenAlex.

Their work

Papers
73 (first author 21, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
131
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 3 papers · 2014: 6 papers · 2015: 3 papers · 2016: 4 papers · 2017: 5 papers · 2018: 9 papers · 2019: 5 papers · 2020: 9 papers · 2021: 8 papers · 2022: 6 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 50 of 73

  1. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  2. Prognostic discrepancies between surgery-first and neoadjuvant-treated resected pancreatic cancer in the same pathological stage. Co-author DOI 10.1007/s00595-025-03163-2↗
  3. Redefining biologically borderline resectable pancreatic cancer: a data-driven reassessment of CA19-9 cutoff and a preoperative lymph node metastasis predictio… Co-author DOI 10.1007/s00595-026-03463-1↗
  4. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  5. Clinical Impact for Prognostic Index of Nodal Stations and Reconsideration of Optimal Regional Lymph Node Station in Pancreatic Cancer. Co-author DOI 10.1002/jhbp.12179↗
  6. Author's reply to the Letter to Editor regarding "Exploring the Role of Neoadjuvant Therapy for Resectable Pancreatic Cancer". Co-author DOI 10.1016/j.pan.2024.11.017↗
  7. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  8. The survival in octogenarians undergoing surgery for pancreatic cancer and its association with the nutritional status. Co-author DOI 10.1007/s00595-023-02782-x↗
  9. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Co-author DOI 10.1016/j.pan.2024.03.012↗
  10. Reappraisal of the current resectability criteria and optimal treatment strategies for pancreatic cancer. Co-author DOI 10.21037/jgo-24-102↗
  11. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreati… First author DOI 10.1002/ags3.12613↗
  12. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  13. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  14. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  15. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  16. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  17. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  18. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Co-author DOI 10.1245/s10434-022-12039-5↗
  19. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. First author DOI 10.1007/s00595-020-02220-2↗
  20. Author response to: Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1093/bjs/znaa033↗
  21. Author's reply: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis (Br J Surg 2020; 107: 1811-1… Co-author DOI 10.1093/bjs/znab054↗
  22. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. First author DOI 10.1097/mpa.0000000000001712↗
  23. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Co-author DOI 10.1186/s13148-021-01165-8↗
  24. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08990-w↗
  25. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  26. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Co-author DOI 10.21873/anticanres.15189↗
  27. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  28. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  29. Clinical impact of additional therapy for residual pancreatic cancer. Co-author DOI 10.1007/s00595-019-01900-y↗
  30. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001559↗
  31. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. First author DOI 10.1245/s10434-019-07981-w↗
  32. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. First author DOI 10.1245/s10434-019-08047-7↗
  33. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer. First author DOI 10.1245/s10434-019-08056-6↗
  34. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. First author DOI 10.21873/anticanres.14138↗
  35. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. First author DOI 10.3390/cancers13010036↗
  36. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Co-author DOI 10.1002/jhbp.622↗
  37. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. First author DOI 10.1016/j.ejso.2019.05.019↗
  38. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. First author DOI 10.1016/j.hpb.2019.01.012↗
  39. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  40. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … First author DOI 10.18999/nagjms.81.2.233↗
  41. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  42. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surge… Co-author DOI 10.1016/j.surg.2018.05.050↗
  43. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. First author DOI 10.1038/s41598-018-28253-9↗
  44. Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001105↗
  45. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1097/mpa.0000000000001110↗
  46. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. First author DOI 10.1097/mpa.0000000000001186↗
  47. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  48. Effect of Plasma-Activated Lactated Ringer's Solution on Pancreatic Cancer Cells In Vitro and In Vivo. First author DOI 10.1245/s10434-017-6239-y↗
  49. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. First author DOI 10.1245/s10434-018-6699-8↗
  50. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2017.01.075↗

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Kodera · 55 shared papers, 2011–2023 · strength 4.50
  2. Tsutomu Fujii · 51 shared papers, 2011–2025 · strength 4.40
  3. Masamichi Hayashi · 30 shared papers, 2011–2025 · strength 2.88
  4. Mitsuro Kanda · 33 shared papers, 2011–2022 · strength 2.32
  5. Fuminori Sonohara · 23 shared papers, 2018–2022 · strength 2.26
  6. Sohei Satoi · 14 shared papers, 2017–2026 · strength 2.23
  7. Akimasa Nakao · 14 shared papers, 2011–2026 · strength 1.99
  8. Daisuke Hashimoto · 5 shared papers, 2021–2025 · strength 1.00
  9. Hiroyuki Sugimoto · 20 shared papers, 2011–2017 · strength 0.90
  10. Masayuki Sho · 6 shared papers, 2017–2026 · strength 0.86
  11. Yuki Sunagawa · 5 shared papers, 2020–2024 · strength 0.81
  12. Masaya Suenaga · 12 shared papers, 2014–2021 · strength 0.78
  13. Satoshi Hirano · 5 shared papers, 2020–2026 · strength 0.77
  14. Hiroki Yamaue · 6 shared papers, 2017–2026 · strength 0.73
  15. Tomohisa Yamamoto · 6 shared papers, 2017–2024 · strength 0.72
  16. Norifumi Hattori · 8 shared papers, 2015–2022 · strength 0.67
  17. Junpei Yamaguchi · 5 shared papers, 2018–2026 · strength 0.67
  18. Yukihiro Yokoyama · 5 shared papers, 2018–2026 · strength 0.67
  19. Yoshiaki Murakami · 5 shared papers, 2017–2026 · strength 0.66
  20. Hiroki Kawashima · 4 shared papers, 2018–2026 · strength 0.56
  21. Osamu Maeda · 4 shared papers, 2018–2026 · strength 0.56
  22. Mitsugu Sekimoto · 4 shared papers, 2020–2024 · strength 0.54
  23. So Yamaki · 4 shared papers, 2020–2024 · strength 0.52
  24. Itaru Endo · 3 shared papers, 2019–2026 · strength 0.52
  25. Michiaki Unno · 3 shared papers, 2017–2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.